SAB Biotherapeutics Inc —— 现金流量表 (NASDAQ:SABS) | MetaTrader

展开完整图表

Financials

概览声明统计

每季度年度

经营活动产生的现金 —3.76 M-23.46 M-25.12 M-34.29 M-44.78 M -44.78 M 投资活动产生的现金 —-10.94 M-2.09 M-152.7 K-11.96 M-121.71 M -121.71 M 融资活动产生的现金 —34.12 M1.05 M66.77 M-1.17 M168.3 M 168.3 M 自由现金流 —-7.19 M-25.63 M-25.32 M-34.63 M-45.71 M -44.78 M

新闻

H.C. Wainwright因股本稀释下调SAB Biotherapeutics目标价至7美元

H.C. Wainwright cuts SAB Biotherapeutics price target to $7 on dilution

SAB Biotherapeutics在1期试验中报告C肽早期信号

SAB Biotherapeutics reports early C-peptide signals in phase 1 trial

UBS因糖尿病药物潜力给SAB Biotherapeutics股票首次评级为"买入"

SAB Biotherapeutics stock initiated with Buy rating at UBS on diabetes drug potential

古根海姆以糖尿病潜力为由给予SAB Biotherapeutics股票买入评级

Guggenheim initiates SAB Biotherapeutics stock with Buy rating on T1D potential

SAB Biotherapeutics在两名董事辞职后缩减董事会规模

SAB Biotherapeutics reduces board size following resignations of two directors

SAB Biotherapeutics股东批准股权计划修订和B系列转换提案

SAB Biotherapeutics shareholders approve equity plan amendment and Series B conversion proposal